Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

被引：1
作者：
Tam, Constantine S.
Simpson, David
Opat, Stephen
Kim, Won Seog
Wang, Michael
Cull, Gavin
Johnston, Patrick B.
Munoz, Javier
Lee, Won-Sik
Marlton, Paula
Gottlieb, David
Wang, Lai
Huang, Jane
Hilger, James
Xue, Ling
Ro, Sunhee
Trotman, Judith
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
152
引用
收藏
页数：3
相关论文
共 50 条
[21]   Health-related quality of life in patients with indolent and aggressive non-Hodgkin lymphoma [J].
Alawi, Eliza M. ;
Mathiak, Krystyna A. ;
Panse, Jens ;
Mathiak, Klaus .
COGENT PSYCHOLOGY, 2016, 3
[22]   Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin's Lymphoma [J].
Newcomb, Richard A. ;
Johnson, P. Connor ;
Yang, Daniel ;
Holmbeck, Katherine ;
Choe, Joanna ;
Nabily, Anisa ;
Lark, Porsha ;
Dhawale, Tejaswini ;
Amonoo, Hermioni L. ;
El-Jawahri, Areej .
ONCOLOGIST, 2023, :441-449
[23]   Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. [J].
O'Connor, O ;
Wright, J ;
Moskowitz, CH ;
Muzzy, J ;
MacGregor-Cortelli, B ;
Hamlin, P ;
Straus, D ;
Trehu, E ;
Schenkein, DP ;
Zelenetz, AD .
BLOOD, 2003, 102 (11) :636A-636A
[24]   Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by revised international workshop criteria [J].
Brepoels, L. ;
Stroobants, S. ;
De Wever, W. ;
Spaepen, K. ;
Vandenberghe, P. ;
Thomas, J. ;
Uyttebroeck, A. ;
Mortelmans, L. ;
De Wolf-Peeters, C. ;
Verhoef, G. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 :S235-S235
[25]   Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma [J].
Imrie, KR ;
Linch, DC ;
Czuczman, MS .
ANTI-CANCER DRUGS, 2002, 13 :S19-S24
[26]   Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by integrated international workshop criteria [J].
Brepoels, Lieselot ;
Stroobants, Sigrid ;
De Wever, Walter ;
Spaepen, Karoline ;
Vandenberghe, Peter ;
Thomas, Jose ;
Uyttebroeck, Anne ;
Mortelmans, Luc ;
De Wolf-Peeters, Christiane ;
Verhoef, Gregor .
LEUKEMIA & LYMPHOMA, 2007, 48 (08) :1522-1530
[27]   SUVmax of 10 is a Highly Specific and Moderately Sensitive Cutoff Between Aggressive and Indolent Non-Hodgkin Lymphoma: Analysis of 331 Patients with FDG-PET/CT [J].
Alobthani, G. ;
Isoahshi, K. ;
Watabe, T. ;
Matsunaga, K. ;
Kato, H. ;
Tatsumi, M. ;
Shimosegawa, E. ;
Hatazawa, J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 :S725-S725
[28]   What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)? [J].
Engel-Nitz, Nicole ;
Byfield, Stacey Dacosta ;
Bancroft, Timothy ;
Amy, Anderson J. ;
Reyes, Carolina ;
Chen, May ;
Matasar, Matthew J. .
BLOOD, 2016, 128 (22)
[29]   A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY [J].
Fowler, N. ;
Sharman, J. ;
Smith, S. ;
Pollyea, D. ;
Boyd, T. ;
Grant, B. ;
Kathryn, K. ;
Buggy, J. ;
Loury, D. ;
Hamdy, A. ;
Advani, R. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 :371-371
[30]   Outcome of Hodgkin's lymphoma and aggressive non-Hodgkin lymphoma patients refractory to salvage chemotherapy [J].
Castagna, L. ;
Bramanti, S. ;
Balzarotti, M. ;
Giordano, L. ;
Michieli, M. ;
Anastasia, A. ;
Magagnoli, M. ;
Sarina, B. ;
Todisco, E. ;
Mazza, R. ;
Nozza, A. ;
Ibatici, A. ;
Santoro, A. .
BONE MARROW TRANSPLANTATION, 2011, 46 :S249-S249
12345